The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Fetal heart rate patterns are an important parameter in the diagnosis of non-reassuring fetal status. Combined-spinal epidural analgesia is a method of initiating labor analgesia used by approximately 90% of the parturients at Prentice Women's Hospital. Optimizing the variables which could affect fetal heart rate patterns at the time of initiation of analgesia, such as fluid administration and oxytocin management, could help us provide better care for our patients and their fetuses.
Hypotheses: The combination of fluid administration and lower doses of oxytocin administration will have fewer adverse fetal heart rate changes in the first 60 minutes following initiation of labor analgesia.
| Condition | Intervention |
|---|---|
|
Pregnancy Labor Pain |
Procedure: Lactated Ringers bolus of 1000 ml Procedure: No additional fluid Procedure: Routine oxytocin Procedure: Half-dose oxytocin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
| Official Title: | The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes |
- Incidence of non-reassuring fetal heart rate tracings during the first 60 minutes after the placement of epidural analgesia [ Time Frame: Request for labor analgesia up to the first 60 minutes after the placement of epidural ] [ Designated as safety issue: Yes ]
| Enrollment: | 252 |
| Study Start Date: | September 2007 |
| Study Completion Date: | July 2012 |
| Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Group A
An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
|
Procedure: Lactated Ringers bolus of 1000 ml
Lactated Ringers bolus of 1000 ml initiated at patient positioning for epidural placement
Procedure: Routine oxytocin
per regular oxytocin protocols
|
|
Experimental: Group B
An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
|
Procedure: Lactated Ringers bolus of 1000 ml
Lactated Ringers bolus of 1000 ml initiated at patient positioning for epidural placement
Procedure: Half-dose oxytocin
The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes after initiation of labor analgesia
|
|
Active Comparator: Group C
The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. Oxytocin management continued per protocol.
|
Procedure: No additional fluid
Regular maintenance infusion of Lactated Ringers @ 125 ml/hr; no additional fluids
Procedure: Routine oxytocin
per regular oxytocin protocols
|
|
Experimental: Group D
The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
|
Procedure: No additional fluid
Regular maintenance infusion of Lactated Ringers @ 125 ml/hr; no additional fluids
Procedure: Half-dose oxytocin
The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes after initiation of labor analgesia
|
Detailed Description:
After obtaining informed, written consent, candidates were randomized to one of four groups at the time of request for labor analgesia. All subjects received a maintenance infusion of Lactated Ringers(LR). For candidates in Groups A or B, an intravenous bolus of 1000 mL of LR was initiated. Candidates in Groups C and D did not receive any additional fluid. If randomized to group A or C, the oxytocin management was continued as per the normal active management of labor protocal (AMOL). If randomized to groups B or D, the dose of oxytocin that was being administered was halved and not increased until 60 minutes after the initiation of epidural analgesia. Fetal heart rate monitoring and frequency of uterine contractions were recorded by external tocodynamometry.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 18-60
- Healthy nulliparous or multiparous women
- Term (>36 week gestation)
- Singleton pregnancy
- Spontaneous labor or with spontaneous rupture of membranes
- Receive oxytocin
- Request neuraxial analgesia
Exclusion Criteria:
- Under 18 years of age
- Presence of any systemic disease (e.g., diabetes mellitus, hypertension, preeclampsia)
- Use of chronic analgesic medications
- Prior administration of systemic opioid labor analgesia
- Non-vertex presentation
- Induction of labor
- Contraindication to neuraxial analgesia.
Contacts and Locations| United States, Illinois | |
| Prentice Women's Hospital | |
| Chicago, Illinois, United States, 60611 | |
| Principal Investigator: | Cynthia A Wong, M.D. | Northwestern University |
More Information
Publications:
| Responsible Party: | Cynthia Wong, Professor of Anesthesiology, Northwestern University |
| ClinicalTrials.gov Identifier: | NCT00787176 History of Changes |
| Other Study ID Numbers: | 0524-034 |
| Study First Received: | November 6, 2008 |
| Last Updated: | July 23, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Northwestern University:
|
Oxytocin Labor, Obstetric Non-reassuring fetal heart rate epidural |
Additional relevant MeSH terms:
|
Labor Pain Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Oxytocin |
Oxytocics Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013